Abstract
We evaluated the control of cardiovascular disease (CVD) risk factors among patients with atherosclerotic cardiovascular disease (ASCVD) in the Centralized Pan-Middle East Survey on the undertreatment of hypercholesterolaemia (CEPHEUS) in the Arabian Gulf. Of the 4398 enrolled patients, overall mean age was 57 ± 11 years, 60% were males, 13% were smokers, 76% had diabetes, 71% had metabolic syndrome and 78% had very high ASCVD risk status. The proportion of subjects with body mass index <25 kg/m2, HbA1c <7% (in diabetics), low-density lipoprotein cholesterol (LDL-C) <2.6 mmol/L (100 mg/dL) and <1.8 mmol/L (70 mg/dL) for high and very high ASCVD risk cohorts, respectively and controlled blood pressure (<140/90 mmHg) was 14, 26, 31% and 60%, respectively. Only 1.4% of the participants had all of their CVD risk factors controlled with significant differences among the countries (P < .001). CVD risk goal attainment rates were significantly lower in those with very high ASCVD risk compared with those with high ASCVD risk status (P < .001). Females were also, generally, less likely to attain goals when compared with males (P < .001).
Keywords: Cardiovascular diseases, obesity, blood pressure, diabetes mellitus, non-HDL cholesterol, LDL cholesterol, Arabian Gulf.
Current Vascular Pharmacology
Title:Control of Risk Factors for Cardiovascular Disease among Multinational Patient Population in the Arabian Gulf
Volume: 14 Issue: 4
Author(s): Mohammed Fakhry, Khalid Al-Rasadi, Khamis Al-Hashmi, Khalid Al-Waili, Raul D. Santos, Haitham Amin, Fahad O.A.S. Baslaib, Omar Al-Hallaq, Obaid Al-Jassim, Afzal H. Yusufali, Abdel R. Medani, Hossam Elghetany, Ibrahim Al-Zakwani, Akram Al-Khadra, Othman Metwally, Khalid Al-Nemer, Faisal Al-Anazi, Shorook Al-Herz, Mahmoud Al-Awadhi, Omer Al-Tamimi, Abdullah Shehab, Ali T. Al-Hinai, Mohamed Arafah and Wael Al-Mahmeed
Affiliation:
Keywords: Cardiovascular diseases, obesity, blood pressure, diabetes mellitus, non-HDL cholesterol, LDL cholesterol, Arabian Gulf.
Abstract: We evaluated the control of cardiovascular disease (CVD) risk factors among patients with atherosclerotic cardiovascular disease (ASCVD) in the Centralized Pan-Middle East Survey on the undertreatment of hypercholesterolaemia (CEPHEUS) in the Arabian Gulf. Of the 4398 enrolled patients, overall mean age was 57 ± 11 years, 60% were males, 13% were smokers, 76% had diabetes, 71% had metabolic syndrome and 78% had very high ASCVD risk status. The proportion of subjects with body mass index <25 kg/m2, HbA1c <7% (in diabetics), low-density lipoprotein cholesterol (LDL-C) <2.6 mmol/L (100 mg/dL) and <1.8 mmol/L (70 mg/dL) for high and very high ASCVD risk cohorts, respectively and controlled blood pressure (<140/90 mmHg) was 14, 26, 31% and 60%, respectively. Only 1.4% of the participants had all of their CVD risk factors controlled with significant differences among the countries (P < .001). CVD risk goal attainment rates were significantly lower in those with very high ASCVD risk compared with those with high ASCVD risk status (P < .001). Females were also, generally, less likely to attain goals when compared with males (P < .001).
Export Options
About this article
Cite this article as:
Fakhry Mohammed, Al-Rasadi Khalid, Al-Hashmi Khamis, Al-Waili Khalid, Santos D. Raul, Amin Haitham, Baslaib O.A.S. Fahad, Al-Hallaq Omar, Al-Jassim Obaid, Yusufali H. Afzal, Medani R. Abdel, Elghetany Hossam, Al-Zakwani Ibrahim, Al-Khadra Akram, Metwally Othman, Al-Nemer Khalid, Al-Anazi Faisal, Al-Herz Shorook, Al-Awadhi Mahmoud, Al-Tamimi Omer, Shehab Abdullah, Al-Hinai T. Ali, Arafah Mohamed and Al-Mahmeed Wael, Control of Risk Factors for Cardiovascular Disease among Multinational Patient Population in the Arabian Gulf, Current Vascular Pharmacology 2016; 14 (4) . https://dx.doi.org/10.2174/1570161113666151026115921
DOI https://dx.doi.org/10.2174/1570161113666151026115921 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Use of Chronic Disease Registries to Optimize Cardiovascular Health
Current Vascular Pharmacology Management of Prehypertension: Current Status and Future Strategies
Current Hypertension Reviews Total Polyphenols and Bioactivity of Seeds and Sprouts in Several Legumes
Current Pharmaceutical Design Sobetirome: A Selective Thyromimetic for the Treatment of Dyslipidemia
Recent Patents on Cardiovascular Drug Discovery A Developmental Approach to Drug-induced Liver Injury in Newborns and Children
Current Medicinal Chemistry Polyphenols: A Diverse Class of Multi-Target Anti-HIV-1 Agents
Current Drug Metabolism Chemistry, Physiology, and Pharmacology of β-Adrenergic Mechanisms in the Heart. Why are β-Blocker Antiarrhythmics Superior?
Current Pharmaceutical Design New Therapeutic Approaches to Arterial Calcification Via Inhibition of Transglutaminase andβ-Catenin Signalin
Current Pharmaceutical Design B-Type Natriuretic Peptide for Diagnosis and Therapy
Recent Patents on Cardiovascular Drug Discovery Adipose Tissue Oxygenation in Obesity: A Matter of Cardiovascular Risk?
Current Pharmaceutical Design Investigating the Associations between Mediterranean Diet, Physical Activity and Living Environment with Childhood Asthma using Path Analysis
Endocrine, Metabolic & Immune Disorders - Drug Targets Antiplatelet and Antithrombotic Therapy After Patent Foramen Oval and Atrial Septal Defect Closure
Current Pharmaceutical Design Monogenic Diabetes: Genetics and Relevance on Diabetes Mellitus Personalized Medicine
Current Diabetes Reviews Mesenchymal Stromal Cells: A Promising Cell Source for the Treatment of Inflammatory Cardiomyopathy
Current Pharmaceutical Design Rimonabant for the Treatment of Obesity
Recent Patents on Cardiovascular Drug Discovery miR-126 as a Therapeutic Agent for Diabetes Mellitus
Current Pharmaceutical Design Pharmacological Treatments for Obesity-Related Hypertension
Current Hypertension Reviews Metabolic Effects of Renal Denervation
Current Clinical Pharmacology Editorial [ Cardiovascular Risk Factor Modification: A sine qua non in the Management of Vascular Surgery Patients ]
Current Vascular Pharmacology 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Regulation by Antioxidant Compounds: New Therapeutic Tools for Hypercholesterolemia?
Current Molecular Medicine